Scientists are one step closer to finding a way to make nerve fibres repair themselves. So far, scientists are able to do this in mice but have yet to begin any sort of human trials. A gene, Cacna2d2, has been identified as important key to this process. Cacna2d2 acts as a “molecular brake” in our system, but now scientists are able to turn this brake off. Turning this break off would allow development of treatments for conditions like paralysis and other spinal cord injuries.
The gene Cacna2d2 is a gene that inhibits fibre regrowth when nerve connections have become damaged. The ability to manipulate this nerve will allow scientists to experiment with how to turn on fibre regrowth. Scientists discovered that the gene Cacna2d2 was in fact acting as this “molecular brake” through an experiment performed on mice. Researchers administered a drug called Pregablin (PGB) to mice that had spinal cord injuries. After the mice were injected with PGB, the researches began to see nerve connections beginning to grow. The researches claim that this study shows that the synapse formation acts as a powerful switch that restraints axonal growth.
With further research and experimentation, the researches of this experiment hope to have a drug in the future than can provide the same effects to humans. This drug is years from being created, but the possibilities.
Those who suffer from diabetes have to regularly test their blood glucose levels, and the standard way of testing these levels is through a blood test. This blood test is conducted after pricking the individual’s finger, which is often time very painful. Many individuals with diabetes also have to inject insulin on a daily basis. In an effort to make the lives of those with diabetes a little bit easier, researches are been experimenting to create an oral insulin pill.
An Israeli company, Oramed Pharmaceuticals, just received approval from the US FDA to ship their experiment drug around the US for testing. The drug is named ORM-0801 and is designed for individuals to take before a meal in order to help regulate blood sugar levels. The company still needs to go through the Investigational New Drug Application before the FDA can approve clinical trials, but things are moving along quickly.
The company hopes that this drug will not only help Type 2 diabetes, but also Type 1 diabetes – which is also known as juvenile diabetes. With Type 1 diabetes, the individual has to typically keep an insulin pump with them at all times and have a port installed into their abdomen so they can have a constant supply of insulin. Oramed hopes that this pill could help children better adhere to their medication schedule.